ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronEye IconIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintSite TitleTitle ChevronIcon Twitter
Health Technology

Towa Pharmaceutical Co., Ltd.

Business Summary

Towa Pharmaceutical Co., Ltd. engages in the manufacture and distribution of pharmaceutical products. Its products include neurological and anti-allergic drugs, cardiovascular and respiratory drugs, gastrointestinal drugs, antibiotics and chemotherapeutic drugs, vitamins; hormone drugs, and other metabolic drugs. The company was founded in June 1951 and is headquartered in Osaka, Japan.

Financial Highlights

Mar 2019 JPYUSD
Revenue105,104M947.78M
Gross Profit48,399M436.44M
Operating income16,283M146.83M
Income before tax18,886M170.30M
Net income13,475M121.51M
EBITDA24,623M222.03M
Diluted EPS253.312.28
Dividends Per Share35.830.32
Total Assets189,158M1,708.97M
Total liabilities97,386M879.84M
Total equity91,771M829.11M
Operating cash flow19,002M171.35M
Currency in JPYCurrency in USD

Historical Data

 Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019
Revenue 71,470M 82,115M 84,949M 93,430M 105,104M
Gross Profit 36,983M 41,854M 39,047M 43,051M 48,399M
Operating income 11,115M 11,134M 7,143M 11,644M 16,283M
Income before tax 15,206M 9,903M 7,237M 9,833M 18,886M
Net income 11,118M 7,684M 5,576M 6,495M 13,475M
EBITDA 25,285M 27,998M 15,123M 19,817M 24,623M
Diluted EPS 218.05 145.43 104.74 122.02 253.31
Dividends Per Share 31.66 31.66 31.66 31.66 35.83
Total Assets 121,187M 156,851M 165,247M 177,655M 189,158M
Total liabilities 51,139M 86,246M 90,299M 97,733M 97,386M
Total equity 70,048M 70,605M 74,945M 79,920M 91,771M
Operating cash flow 8,037M 3,732M 10,195M 19,230M 19,002M
 Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019
Revenue 650.57M 683.81M 784.47M 842.98M 947.78M
Gross Profit 336.64M 348.53M 360.58M 388.43M 436.44M
Operating income 101.17M 92.71M 65.96M 105.05M 146.83M
Income before tax 138.41M 82.46M 66.83M 88.71M 170.30M
Net income 101.20M 63.98M 51.49M 58.60M 121.51M
EBITDA 230.16M 233.15M 139.65M 178.80M 222.03M
Diluted EPS 1.98 1.21 0.96 1.10 2.28
Dividends Per Share 0.28 0.26 0.29 0.28 0.32
Total Assets 1,010.52M 1,395.53M 1,482.96M 1,670.47M 1,708.97M
Total liabilities 426.42M 767.34M 810.36M 918.97M 879.84M
Total equity 584.09M 628.18M 672.57M 751.48M 829.11M
Operating cash flow 73.15M 31.07M 94.14M 173.50M 171.35M

Valuation Measures

Mar 2019
PER10.63
ROA7.34%
ROE15.69%
Operating margin15.49%
Profit margin12.82%

Key executives

  • President & Representative Director: Itsuro Yoshida
  • Executive Officer, GM-Research & Development: Takeshi Sugiura
  • Executive Officer & Deputy General Manager-Sales: Masaji Morikawa
  • Executive Officer & Manager-Accounting: Shinya Kida
  • Director, GM-Administration & Manager-IR: Masao Tanaka

Shareholders

  • YOSHIDA FAMILY /TOWA PHARMACEUTICAL/ (39.0%)
  • Towa Pharmaceutical Co., Ltd. (4.4%)
  • YOSHIDA ITSURO (2.8%)
  • Towa Pharmaceutical Business Association (2.6%)
  • Asset Management One Co., Ltd. (2.2%)
  • Nomura Asset Management Co., Ltd. (1.7%)
  • Towa Pharmaceutical Employee Stock Ownership Plan (1.5%)
  • The Vanguard Group, Inc. (1.4%)
  • Goldman Sachs Asset Management LP (1.3%)
  • Fidelity (Canada) Asset Management ULC (1.3%)

Contact Details

Related Companies

  • Towa Pharmaceutical Restricted Stock Compensation Plan
  • Pensa Investments SL
  • Daichi Kasei KK
  • J-Dolph Co., Ltd.
  • Towa Pharmaceutical Business Association
  • Towa Pharmaceutical Employee Stock Ownership Plan

Competitors

    Last Updated on 27 Mar, 2020

    You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this monthThis is your last free article this month

    Stay ahead with our exclusives on Asia;
    the most dynamic market in the world.

    Stay ahead with our exclusives on Asia

    Get trusted insights from experts within Asia itself.

    Get trusted insights from experts
    within Asia itself.

    Get Unlimited access

    You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this month

    This is your last free article this month

    Stay ahead with our exclusives on Asia; the most
    dynamic market in the world
    .

    Get trusted insights from experts
    within Asia itself.

    Try 3 months for $9

    Offer ends April 30th

    Your trial period has expired

    You need a subscription to...

    • Read all stories with unlimited access
    • Use our mobile and tablet apps
    See all offers and subscribe

    Your full access to the Nikkei Asian Review has expired

    You need a subscription to:

    • Read all stories with unlimited access
    • Use our mobile and tablet apps
    See all offers
    NAR on print phone, device, and tablet media